key: cord-0828164-efvxskih
authors: Mendonça, Michelle Mendanha; da Cruz, Kellen Rosa; Pinheiro, Denise da Silva; Moraes, Gean Carlos Alves; Ferreira, Patricia Maria; Ferreira-Neto, Marcos Luiz; da Silva, Eduardo Sérgio; Vilela, Reggiani; Pedrino, Gustavo Rodrigues; Fajemiroye, James O.; Xavier, Carlos Henrique
title: Dysregulation in erythrocyte dynamics caused by SARS-CoV-2 infection: possible role in shuffling the homeostatic puzzle during COVID-19
date: 2022-01-25
journal: Hematol Transfus Cell Ther
DOI: 10.1016/j.htct.2022.01.005
sha: 111e8ee9a151b234cea0333fff11b2f468ef214c
doc_id: 828164
cord_uid: efvxskih

INTRODUCTION: : The evolving COVID-19 pandemic became a hallmark in human history, not only by changing lifestyles, but also by enriching scientific knowledge on viral infection and its consequences. OBJECTIVE: : Although management of cardiorespiratory changes is pivotal to a favorable prognosis during severe clinical findings, dysregulation of other systems caused by SARS-CoV-2 infection may imbalance erythrocyte dynamics, such as a bidirectional positive feedback loop pathophysiology. METHOD AND RESULTS: : Recent evidence shows that SARS-CoV-2 is capable of affecting the genetics and dynamics of erythrocytes and this coexists with a non-homeostatic function of cardiovascular, respiratory and renal systems during COVID-19. In hypothesis, SARS-CoV-2-induced systematical alterations of erythrocytes dynamics would constitute a setpoint for COVID-19-related multiple organ failure syndrome and death. CONCLUSION: : The present review covers the most frequent erythrocyte-related non-homeostatic findings during COVID-19 capable of providing mechanistic clues of SARS-CoV-2-induced infection and inspiring therapeutic-oriented scientific evidence.

In 2020, local disease control and prevention centers in Beijing unraveled an unknown pathogen: a new variation of coronavirus now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). The COVID-19 (Coronavirus Disease 19) pandemic has dramatically changed the way global health is being managed. Even with the wishful vaccines in the spotlight, worldwide data has shown that the COVID-19 pandemic is still uncontrolled (2, 3) . Hence, additional clinical and scientific efforts remain pertinent towards a better understanding of the pathophysiology of this disease. The persisting post-infection consequences on different systems further require more extensive knowledge on these pathophysiological processes.

The combination of diagnostic tools, composed of RT-PCR, serology, imaging tests and clinical evaluation may provide clues for pathophysiology and clinicalepidemiological information to better guide clinical approaches and prognosis.

Findings from these methods could provide important clues to the COVID-19 signature towards addressing many clinical and research questions, thus diminishing the life-threatening potential of the SARS-CoV-2 infection (4) . A worth possibility that would aid to these clues may arise from concomitant hematological assessments.

The set of effects caused by the SARS-CoV-2 infection presents a complex combination of clinical manifestations, from mild flu-like symptoms to multiple organ failure and death (5) . These multisystemic illnesses necessitate a complex set of approaches. According to Danying Liao and colleagues, clinical and laboratory findings suggest that refractory hypoxemia in critically ill patients can induce vasoconstriction prior to a reduction in blood flow and vascular occlusion. Altogether, this may reduce the tissue perfusion leading to notable clinical manifestations (6) . Therefore, the search for potentially useful clues for the disease progression and prognosis management merit in-depth testing in blood samples. Although the clinical developments related to the SARS-CoV-2 infection keep growing, the COVID-19

pathophysiology is yet poorly correlated with the aggravating hematological changes, which may be the cause for many perfusion-dependent manifestations. The present work compiles the main pathophysiological mechanisms arising from the SARS-CoV-2 infection and relates them to frequent hematological findings in COVID-19

patients. The working hypotheses in this review are aimed at inspiring the scientific community in the search for additional evidence on erythrocyte-related nonhomeostatic control during the COVID-19 pandemic.

SARS-CoV-2, an RNA +, is known to be responsible for respiratory infections (5, 7) that present spherical and enveloped morphology, whose structure is composed of: i) the peak glycoprotein S or Spike (S) protein, which covers the surface of the Sars-CoV-2 and serves as a tool to enter human cells (found in all CoVs); ii) hemagglutinin esterase (HE), expressed in some CoVs, including SASR-CoV-2; iii) the membrane protein (M) (a type III transmembrane glycoprotein, and; iv) the envelope protein (E), located between the S proteins on the viral envelope (7, 8) ( Figure 1 ).

Infections result from the interaction of the virus with host cell surface receptors (endosomal membrane fusion) or cytoplasmic membrane fusion, as illustrated in Figure 1 . The internalization process of SARS-CoV-2 depends on TMPRSS2, a serine protease that cleaves and activates protein S (5) . In this case, the viral S protein, consisting of spicules of glycoproteins, is cleaved into the S1 and S2 (a protein involved in a viral entry, via the endosome). The S1 is responsible for membrane binding by coupling to the extracellular juxtamembrane domain of the angiotensin-converting enzyme 2 (ACE2), expressed in different host tissues and lung cells (8) . However, drugs interfering with angiotensinergic components do not appear to modify the course and clinical severity of COVID-19 (9) . Furthermore, to date, the literature lacks clinical evidence of any pharmacological approach for the angiotensinergic counterregulatory branch during COVID-19, although the involvement of ACE2 in SARS-CoV-2 infection is considered irrefutable (10-12) and a promising therapeutic target (13) . Research on these enzymes may provide important outcomes in the understanding of the COVID-19 pathophysiology.

In this context, it is necessary to highlight that the activity of serine proteases and S proteins, as mechanisms for anchoring the SARS-CoV-2 to host cells, seems to be more relevant indeed (5, 14) . This action of the serine protease, a limiting step for the adhesion of the virus to the cell plasma membrane, allows its entry into the cell, suggesting that the greater aggressiveness of the SARS-CoV-2 may be a consequence of an increase in the direct entry of the virus into the cells, mediated by the serine protease TMPRSS2 (15) . In addition to entry, via the S1, the virus can also enter through the fusion of some endosomal proteases, such as the Cathepsin L, and this turns this enzyme into a potential pharmacotherapy target. The upper part of Figure 1 outlines the viral structure and the hypothetical processes of the SARS-CoV-2 fusion and infection (5) .

The SARS-CoV-2 genome encodes 14 polyproteins Open Reading Frames (ORFs), responsible for replicating viral RNA (16) . At the 5' end, the largest gene ORF1ab is involved in the coding of 14 non-structural proteins. The 3' end that harbors genes encoding accessory proteins (ORF3a, ORF6, ORF7a, ORF8 and ORF10) comprises structural protein genes that allow the entry to, and infection of, the host cell (17) . The ORFs are responsible for the replication and virulence (16) . The ORF7, for example, may be involved in the viral release, by reducing the expression of the tetherin protein (BST2 gene), which in regular conditions would block different enveloped viruses, such as the SARS-CoV-2, from leaving the host cell. When the virion sprouts out from the cell surface, the tetherin anchored to the cell membrane attaches to a new viral membrane, by hooking the virion to the host cell (18) . Additionally, the ORF7a overexpression may result in apoptosis, via the caspase, besides blockade of cell cycles at the G0 and G1 phases (19) . These modifications in the early stage of cell maturation may impact hematopoiesis. In this sense, the development of pharmacological tools that effectively and directly inhibit the ORFs activity would be innovative and determinant in a better prognosis for those infected by SARS-CoV-2.

The SARS-CoV-2 infection, that evokes ORF-mediated cell damage, more specifically exerted by the ORF3a, is the activation of the nucleotide-binding oligomerization domain. According to Yap and collaborators, the ORF3a promotes the assembly of the inflammasome in a big molecular structure, generating a platform for the mass recruitment and activation of the caspase-1 (20). As a mechanism that dramatically intensifies the pathogenesis of the disease, the activation of the inflammasome can trigger cell pyroptosis, a type of programmed cell death, 

The literature still lacks consistent and conclusive findings on the effects of the SARS-CoV-2 infection on hematopoiesis. There is no study reporting on a causal correlation between the SARS-CoV-2 infection and changes in the bone marrow function and reticulocyte production, which increases the need for further research.

The reticulocyte production results from the influences of several factors, including cytokines that are altered during COVID-19 (23, 24), whose maturity is reached within one or two days in the bloodstream circulation, as determined by the kidney secreted hormone erythropoietin (25). In this regard, it is expected to find hematopoietic changes in COVID-19 patients displaying renal complications related to the inflammatory status (26). Possible influences on the reticulocyte production may interfere with the erythrocyte replacement in the circulation (27), as this period is necessary to complete the synthesis and maturation of hemoglobin (23, 25). A correlation among inflammatory signaling, erythropoietin, hematological outcomes and kidney diseases during COVID-19 is an important field that should be better explored.

With a biconcave morphology, anucleate and devoid of organelles, the erythrocytes are composed of the plasma membrane, cytoskeleton, hemoglobin and glycolytic enzymes (28). After the end of their lifespan (approximately 120 days), these cells are either removed by phagocytosis or destroyed by hemolysis in the spleen (29). Starting from the premise that the primordial erythrocyte activity is the gases transportation, disorders related to the morphophysiology, production, function and/or lifespan of red blood cells may result in tissue hypoxia due to the lack of oxygenation. The infection generated by the SARS-CoV-2 reduces the blood oxygen level, which can lead to rapid desaturation, although in some cases, dyspnea may be initially absent (30, 31).

According to Delphine Gérard and collaborators, patients with COVID-19 present mushroom cells and abnormal red cell morphology, with the presence of anisocytosis, spherocytosis, stomatocytes and polychromasia (32). These changes in the erythrocyte morphophysiology may be related to the imbalanced redox status found in infectious and inflammatory situations, as seen during COVID-19 (33-35), which promotes oxidative stress in tissues by: i) elevating the levels of free circulating radicals, including reactive oxygen species (ROS), and; ii) reducing the antioxidative enzymatic mechanisms, especially superoxide dismutase (SOD) and catalase (CAT).

During metabolic processes, these free radicals mediate various biochemical reactions, including electron transfer for energy generation, activation of genes and defense mechanisms during the infection process (32-37). However, oxidative damage is often associated either with the overproduction of free radicals and ROS, that attack important structures inside the cells, or with the downregulation in the antioxidant systems (37) . Approximately 2% to 5% of the oxygen that is metabolized in the mitochondria is diverted to metabolic pathways that give rise to free radicals (38) . This suggests that changes in the gases exchange at the cellular level, as a consequence of COVID-19-related changes in erythrocyte dynamics, would contribute to these harmful metabolic routes. In addition, it is important to emphasize that inflammatory processes, such as those manifested during COVID-19, incisively participate in the inflammation-related oxidative stress due to the mechanism known as respiratory burst (39) , in which phagocytes, especially macrophages, are active sources of free radicals and ROS, while exerting phagocytosis (40) . (41), with the highlight for SOD, CAT and Glutathione (42) . Despite not being a free radical, as it does have an unpaired electron in its last electron shell, the H 2 O 2 is a highly reactive species, that can alter any nearby cell structure, proteins and organelles inside the cells. Unlike other free radicals, the H 2 O 2 is long-lasting and can cross cell membranes with toxicity levels that can be increased 10,000x by the presence of iron. The binding of iron and copper to transferrin, ferritin and ceruloplasmin, as a mechanism of transportation, using and storage of these metals, is capable of preventing and/or minimizing the free radical generation reactions catalyzed by these metals. At the cytoplasm of liver cells, free iron (not bound to ferritin) is easily dissociated as an ion, which makes it catalytically active and available to participate in oxidation-reduction reactions and, consequently, in the generation of free radicals (33, 43). Although iron is an essential metal for most biological organisms (34, 35) , it can modify the redox status and mediate the harmful oxidation of biomolecules, including DNA, proteins, lipids and others, when not tightly controlled (34) . In the light of this possible free iron-dependent pathophysiology, it is worth hypothesizing that the SARS-CoV-2 infection would affect erythrocyte-related iron control mechanisms. This shall be supported by evidence that COVID-19 patients display an unfavorable redox status and an increase in serum ferritin, as a result of erythrocyte damage (43) . The lower part of Figure 1 outlines the mechanisms underlying changes in the redox status in the hypothetical positive feedback loop-based oxidative effects probably involved in erythrocyte and tissue damages.

The literature comprises data showing that the structural damage in the plasma erythrocyte membranes may result in shape loss, rheological changes (44), early lysis (28), excessive release of free ions and elevation of serum ferritin (45) . These damages may be a consequence of the activity of non-structural proteins synthesized by the virus within blood cells, thus occasioning death. Extracellular hemoglobin, as a consequence of red cell death, is indeed reported for enhancing oxidative reactions (46) . Following up on from these, therapeutic approaches attempting to reduce oxidative stress would be capable of minimizing damages on erythrocytes during COVID-19, thus increasing their lifespan and function, which would, by implication, result in more efficient oxygen transportation and delivery. Although antioxidant therapy was unable to shorten the duration of the symptoms (47), it should be considered for protecting blood components of those diagnosed with COVID-19 (48) .

However, whether this choice would be effective in acting against the metabolic impairments caused by SARS-CoV-2 and whether this therapy would attenuate impacts on erythrocyte dynamics, remains to be fully investigated.

Changes in the activity and expression of plasma proteins closely related to erythrocyte, platelet and inflammatory vascular activity often accompany viral effects.

The SARS-CoV-2 increases the α1-antitrypsin and acid α1-glycoprotein levels. These are plasma glycoproteins able to bind with lipophilic substances, such as hormones, medications and others (49) . This increases by 3-to 4-fold are found in cases of acute or chronic inflammation, which highlight glycoproteins as candidates for inflammatory biomarking. Conversely, viral structural proteins reduce liversynthetized α2-macroglobulin, whose activity is implicated in the inhibition of enzymes of the kallikrein-kinin system and complement system (50) coagulation and fibrinolysis (6, 51) . This α2-macroglobulin decrease is also present in the COVID-19 inflammatory phase, making it another severity biomarker (52). The ceruloplasmin, that contains about 95% of the serum copper, also plays a protagonist role in the regulation of iron by performing its oxidation for subsequent incorporation by the transferrin (a complex called haptoglobin), which is irreversibly bound to the hemoglobin and prevents iron loss via kidney excretion (26, 53, 54) . The correlation between free iron and the ceruloplasmin-haptoglobin ratio is considered a strong indicator of hemolysis (28) and a potential tool for COVID-19 prognosis, as an increase in its value provides a clue to the acute phase of inflammatory diseases with a direct hemostatic repercussion (55) . This idea is fully supported by data showing the incidence of iron-deficient anemia in patients who recovered from severe COVID-19 (56) and by the results indicating an association of alterations in anemia and iron metabolism biomarkers during the COVID-19 progression (45, 54, 57) . The event cascades resulting from red cell compromise in severe COVID-19 (58) and the possible early hemolysis triggered by the SARS-CoV-2 infection involve hemopexin (59) , which is responsible for free heme transport and recycle (60) . Therefore, the physiological levels of hemopexin could not be enough to metabolize excess free iron in this infectious condition. The excessive level of iron alters the metabolism of the hemoglobin and myoglobin, iron-carriers known as transferrin (61) . Such metabolic changes are closely related to inflammatory processes involving chemotaxis, cellular recruitment among other components of the immune system. In this manner, the hemopexin metabolism offers therapeutic targets and a prognosis for COVID-19 (56, 57, 62) .

It is necessary to keep in mind that hemoglobin is a hemeprotein, whose structure is a globular tetramer formed by 4 units of the polypeptide chain: two α and two β units, attached by weak non-covalent bonds. Each protein or globin subunit has a heme covalently linked to iron at the center for oxygen binding. Heme is an important component of hemoglobin, composed of a porphyrin ring with iron (ferrous or Fe 2 + ), linked to 4 nitrogen atoms (63) . Increases in ferritin production by the liver, in an attempt to reduce oxidative damage, may be a metabolic reactivity evoked by the COVID-19 inflammation-induced excessive free iron (57) . All the cascade altering blood homeostasis that is a consequence of erythrocyte-related impairments in the iron metabolism may unravel potential biomarkers (56) . Therefore, the attainment of a serum protein profile can provide important data on hemostasis and its possible COVID-19 prognostic correlations.

The SARS-CoV-2 surface glycoproteins and ORF polyproteins, specifically ORF8, can bind to porphyrin. At the same time, the ORF1ab, ORF10 and ORF3a can coordinate the attack on heme in the hemoglobin 1-β chain and dissociate iron to form porphyrin. The attack on the heme group will decrease functional hemoglobin levels, gradually affecting the oxygen and carbon dioxide transport. Consequently, lung cells may undergo extremely intense inflammatory toxicity due to their inability to exchange carbon dioxide and oxygen. This finding coincides with chest radiographic images showing ground-glass opacities likely found in diffuse lung disease caused by the SARS-CoV-2 infection (64, 65) .

In addition to the changes in the red blood cell integrity, iron, and redox status, COVID-19 may be associated with a deficiency of the Band-3 protein prior to the appearance of mushroom erythrocytes and clamp cells, as well as Heinz bodies, that are intra-erythrocytic inclusions resulting from globin chains precipitation following hemoglobin oxidation, likely detected in cytopathological tests in COVID-19 patients.

These bizarre erythrocytes can also be seen in bone marrow myelofibrosis and, occasionally, in nonspecific dyseritropoiesis (32, 66). The following figure (Fig. 2) The emergence of unstable hemoglobin is another feasible hypothesis, as the SARS-CoV-2 may be entering the process of hemocytopoiesis, in addition to being highly mutagenic. Such mutagenicity results from the viral capacity to store genetic information also in RNA molecules, and this is the case with the SARS-CoV-2 (74, 75) . Thus, the SARS-CoV-2 would cause mutations and generate polymorphisms. This bizarre protein arrangement affects cell permeability and, consequently, the cell function and lifespan (76) .

The degradation of erythrocytes may release the globin chains, which are metabolized by proteolytic enzymes (81) and, as a result, the α-globin chain degradation releases hemopressins, whereas the degradation of the β-globin chain is the substrate for the hemorphin production (81, 82). These hemoglobin-derived bioactive peptides are transported in the bloodstream and are in charge of regulating several functions throughout the body (83) . Some of these factors are the hemoglobinderived peptides, which are systemically delivered from hemoglobin degradation, that occurs at the end of erythrocyte lifespan. Following the death of these cells, the activity of the enzymes ensures that hemoglobin is adequately hydrolyzed and peptides are released as a result of these enzymatic effects (Table 1 ). By assuming that the activity of these hemoglobin-derived peptides may be part of the puzzle resulting in homeostasis, it is plausible to propose that the acceleration of the erythrocyte degradation by the SARS-CoV-2 infection causes dysregulation in many systems. Although these studies mostly show the role of hemoglobin-derived peptides in physiological functions, it is likely that these peptides indeed participate in the pathophysiology of some diseases (81, 107), which are comorbidities representing the risk of becoming seriously ill during COVID-19 (65, 108) . In addition, there is evidence of an increase in the level of hemorphins in the brain of patients with Alzheimer's disease (109) and this may share pathophysiological aspects resulting in the cognitive sequelae in patients who recovered from COVID-19 (110, 111) .

Therefore, the questions that remain open are on whether: i) the SARS-CoV-2 would influence the activity of enzymes that degrade hemoglobin, and; ii) the SARS-CoV-2 would modify the structure and activity of hemoglobin-derived peptides and their bioavailability. Addressing these questions would open an unexplored field, providing information that would lead to the elaboration of new therapeutic strategies for diagnosis and treatments.

It is still uncertain how many SARS-CoV-2 variants will surface and how long it will be primarily responsible for worldwide deaths from infectious diseases. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

COVID-19) Dashboard

A dynamic COVID-19 immune signature includes associations with poor prognosis

Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract

Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

Coronavirus Disease 2019-COVID-19

Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans

Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes fromCoViD-19: systematic review and meta-analysis

Renin-Angiotensin-Aldosterone System Inhibitors in Covid-19. Reply

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids

COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19

Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction

Caspases in COVID-19 Disease and Sequela and the Therapeutic Potential of Caspase Inhibitors

Iron metabolism: an overview on the main mechanisms involved in its homeostasis

The aging of the red blood cell. A multifactor process

Red blood cell oxidative stress impairs oxygen delivery and induces red blood cell aging

Mitochondria and microbiota dysfunction in COVID-19 pathogenesis

The spatial landscape of lung pathology during COVID-19 progression

The phagocyte respiratory burst: Historical perspectives and recent advances

Free radicals in biology: oxidative stress and the effects of ionizing radiation

Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review

Elevated serum ferritin level effectively discriminates severity illness and liver injury of coronavirus disease 2019 pneumonia

Impact of COVID-19 on red blood cell rheology

Increased Serum Levels of Hepcidin and Ferritin Are Associated with Severity of COVID-19

The pathophysiology of extracellular hemoglobin associated with enhanced oxidative reactions

Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial

The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators

Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation

Complement control for COVID-19

COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure

Laboratory alterations and COVID-19. Revista Brasileira de Análises Clínicas -SBAC

The relationship between serum erythropoietin, hepcidin, and haptoglobin levels with disease severity and other biochemical values in patients with COVID-19

Diagnosing anemia in inflammatory bowel disease: beyond the established markers

Anemia and iron metabolism in COVID-19: a systematic review and metaanalysis

Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Association of Red Blood Cell Distribution Width With Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection

Safe coordinated trafficking of heme and iron with copper maintain cell homeostasis: modules from the hemopexin system

When might transferrin, hemopexin or haptoglobin administration be of benefit following the transfusion of red blood cells?

Persisting alterations of iron homeostasis in COVID-19 are associated with nonresolving lung pathologies and poor patients' performance: a prospective observational cohort study

Molecular basis of visual excitation

Coronavirus infections and immune responses

COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Heme Metabolism2020 10/03/2021

Mushroom-shaped red blood cells in protein band-3 deficiency

RRM Prediction of Erythrocyte Band3

Protein as Alternative Receptor for SARS-CoV-2 Virus

Aspectos estruturais da membrana eritrocitária

Vascular permeability--the essentials

Crystallographic structure and functional interpretation of the cytoplasmic domain of erythrocyte membrane band 3

Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units

Serum ferritin at admission in hospitalized COVID-19 patients as a predictor of mortality

Bone Marrow and Peripheral Blood Findings in Patients Infected by SARS-CoV-2

The role of cysteine peptidases in coronavirus cell entry and replication: The therapeutic potential of cathepsin inhibitors

Behavioral effects evoked by the beta globin-derived nonapeptide LVV-H6

The hemoglobin derived peptide LVV-hemorphin-7 evokes behavioral effects mediated by oxytocin receptors

Hemoglobin-derived peptides as novel type of bioactive signaling molecules

In vitro metabolism of LVV-hemorphin-7 in human plasma studied by reversed-phase high-performance liquid chromatography and micro-electrospray mass spectrometry

VV-hemorphin-7 and LVVhemorphin-7 released during in vitro peptic hemoglobin hydrolysis are morphinomimetic peptides

Comparative in vitro degradation of the human hemorphin LVV-H7 in mammalian plasma analysed by capillary zone electrophoresis and mass spectrometry

Cathepsin D is a good candidate for the specific release of a stable hemorphin from hemoglobin in vivo: VV-hemorphin-7

Hemorphin peptides are released from hemoglobin by cathepsin D. radioimmunoassay against the C-part of V-V-hemorphin-7: an alternative assay for the cathepsin D activity

High molecular weight aspartic endopeptidase generates a coronaro-constrictory peptide from the beta-chain of hemoglobin

Inhibition and inhibition kinetics of angiotensin converting enzyme activity by hemorphins, isolated from a peptic bovine hemoglobin hydrolysate

Proteolytic degradation of hemoglobin by endogenous lysosomal proteases gives rise to bioactive peptides: hemorphins

In vitro metabolism of LVV-Hemorphin-7 by renal cytosol and purified prolyl endopeptidase

Hemorphins: substrates and/or inhibitors of dipeptidyl peptidase IV. Hemorphins N-terminus sequence influence on the interaction between hemorphins and DPPIV

Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme

The hemorphins: a new class of opioid peptides derived from the blood protein hemoglobin

Isolation and characterization of a hemoglobin-derived opioid peptide from the human pituitary gland

Release of hemorphin-5 from human hemoglobin by pancreatic elastase

LVVthe brain

LVV-hemorphin-7 lowers blood pressure in spontaneously hypertensive rats: radiotelemetry study

Attenuation of scopolamine-induced learning deficits by LVV-hemorphin-7 in rats in the passive avoidance and water maze paradigms

7 enhance spatial working memory in rats: effects on hippocampal glucose levels and blood flow

Effect of I.C.V. injection of AT4 receptor ligands, NLE1-angiotensin IV and LVVhemorphin 7, on spatial learning in rats

Hemorphins act as homeostatic agents in response to endotoxininduced stress

The role of NF-AT transcription factors in T cell activation and differentiation

Role of calcineurin in Ca2+-induced release of catecholamines and neuropeptides

Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription

A globin fragment, LVV-hemorphin-7, induces [3H]thymidine incorporation in a neuronal cell line via the AT4 receptor

The globin fragment LVV-hemorphin-7 is an endogenous ligand for the AT4 receptor in the brain

Hemoglobin oxidation generates globin-derived peptides in atherosclerotic lesions and intraventricular hemorrhage of the brain, provoking endothelial dysfunction

SARS-CoV-2 proteins bind heme and hemoglobin. bioRxiv -The preprint server for biology

Quantification of hemorphins in Alzheimer's disease brains

Post-acute Sequelae of SARS-CoV-2

Infection and Subjective Memory Problems

Neuropsychiatric and Cognitive Sequelae of COVID-19

This manuscript was written in honor of the volunteers who worked on the SARS-CoV-2 detection at the Clinical Analyses Laboratory (LACES-ICB) of the Federal